• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

COA Applauds CMS' Decision on CAR T-Cell Therapy

Article

Following CMS’ decision to make chimeric antigen receptor (CAR) T-cell therapy available to Medicare beneficiaries nationwide, including in the community oncology setting, the Community Oncology Alliance (COA) applauded the decision.

Following CMS’ decision to make chimeric antigen receptor (CAR) T-cell therapy available to Medicare beneficiaries nationwide, including in the community oncology setting, the Community Oncology Alliance (COA) applauded the decision. According to COA, the agency listened to the feedback of community practices by ensuring that CAR T-cell therapy is covered outside of the hospital setting.

COA is also pleased that by protecting Medicare beneficiaries, the agency has streamlined the reporting requirements and aligned requirements between CMS and the FDA, which will reduce burden for providers, Medicare, and patients.

Read the full press release.

Related Videos
Julie Patterson, PharmD, PhD
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Screenshot of Fran Gregory, PharmD, MBA, during a video interview
Yael Mauer, MD, MPH
Pregnant Patient | image credit: pressmaster - stock.adobe.com
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Robert Zimmerman, MD
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.